Regeneron's Arcalyst reduces gout flare-ups in Phase III trial

06/9/2010 | Bloomberg Businessweek

Regeneron Pharmaceuticals' gout drug Arcalyst reduced flare-ups by 80% when administered at 160 milligrams once a week, according to a late-stage trial. The company is banking on the success of Arcalyst and two other experimental drugs in late-stage development to earn as much as $2 billion annually.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC